新型CD38靶向免疫PET示踪剂可检测多发性骨髓瘤
CD38-Targeted Immuno-PET Tracer Can Detect Overlooked Multiple Myeloma
一项二期临床试验表明,新型CD38靶向免疫PET示踪剂能更敏感地检测多发性骨髓瘤,补充现有影像技术。该示踪剂在28%的患者中发现了更多病灶,而标准影像技术在22%的患者中发现了更多病灶。
研究显示新型CD38靶向免疫PET示踪剂能更敏感地检测多发性骨髓瘤,补充现有影像技术。
— "While no imaging modality is perfect, this adds a new tool," says researcher
November 4, 2026 • 3 min read
- A novel CD38-targeted immuno-PET tracer could help detect multiple myeloma missed by standard imaging, a phase II trial suggested.
- While overall sensitivity between the two imaging modalities was similar, they offered complementary detection capabilities.
- The CD38-targeted immuno-PET tracer identified more sites of disease than standard imaging in 28% of patients.
A novel CD38-targeted immuno-PET tracer could help detect multiple myeloma in some patients with no signs of disease, according to results from a phase II trial.
While there was no overall difference in disease detection with CD38-targeted zirconium 89 (89Zr) deferoxamine (DFO)-daratumumab PET/CT versus standard-of-care fluorine 18 (18F)-fluorodeoxyglucose (FDG) PET/CT (43% vs 47%, P=0.81), both scans identified multiple lesions not visible on the other, reported Gary A. Ulaner, MD, PhD, of the University of Southern California in Los Angeles, and colleagues in Radiology.
For example, multiple myeloma was demonstrated in 13% of patients only with 89Zr-DFO-daratumumab PET/CT and 17% of patients only with 18F-FDG PET/CT.
Moreover, the CD38-targeted immuno-PET tracer identified more sites of disease than standard imaging in 28% of patients, while 18F-FDG PET/CT identified more sites of disease in 22%. The two imaging approaches detected a similar amount of disease in the remaining patients.
"This study demonstrates that immuno-PET targeting CD38 can identify, localize, and quantify myeloma, which is overlooked by FDG PET in many patients," Ulaner told MedPage Today. "This allows oncologists to optimally stage, target, and treat disease."
"While no imaging modality is perfect, this adds a new tool for the care of patients with multiple myeloma," he added.
In a press release, co-author C. Ola Landgren, MD, PhD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, noted that "if we are going to cure multiple myeloma, we need two things. One, we need really effective medicines. Second, we need to be able to make sure there is no disease left behind after these treatments."
"We are developing new and better technology designed to see where the disease is and make sure we are not missing it," he said. "We show that you can successfully find much more disease. It's a more sensitive and more precise technology, and we have very strong proof of principle that it works and that it's meaningful."
In an editorial accompanying the study, Peter Choyke, MD, of the National Cancer Institute, observed that neither of the two agents detected more than half of the disease present in patients with histologically confirmed disease.
However, while those results may be "disappointing from a clinical perspective, there are several reasons for optimism," he wrote.
Choyke suggested that when combined with highly sensitive liquid biopsies, molecular imaging "might detect ... early disease that would otherwise be missed with conventional imaging and bone marrow biopsy."
In addition, he noted that 89Zr-DFO-daratumumab as a molecular imaging agent is based on daratumumab (Darzalex), which is an actual treatment for multiple myeloma, "so a positive scan implies the drug might be effective."
Ulaner and colleagues noted that while treatment for multiple myeloma has significantly improved over the past two decades, detection of multiple myeloma disease burden remains "suboptimal."
They pointed out that standard-of-care 18F-FDG PET/CT assessment is based on radiolabeled glucose uptake and has limited utility in patients with plasma cell disorders, since myeloma cells may have low glucose uptake. Thus, disease may be undetected with the standard imaging in 30% to 50% of patients with established bone lesions.
The idea behind immuno-PET imaging is that it integrates the target specificity of monoclonal antibodies like daratumumab with the sensitivity and quantitative power of PET, allowing for whole-body mapping of tumor and immune biomarkers.
This prospective, two-center trial was conducted between March 2022 and July 2025, and included 60 participants (median age 63 years, 53% women) who had previously pathologically proven CD38-positive multiple myeloma; had at least one tumor lesion visualized on CT, MRI, or 18F-FDG PET/CT performed within 90 days of protocol enrollment; had an Eastern Cooperative Oncology Group score of 0-2; and were planned for first-line or a new line of myeloma therapy.
Ulaner and team reported that there were no severe adverse events with 89Zr-DFO-daratumumab, while non-severe adverse events occurred in 5% of participants during non-radiolabeled daratumumab administration.
来源:MedPage Today · medpagetoday.com